CHICAGO (GenomeWeb) – Syapse, a maker of software to support precision oncology care, has raised $30 million in a Series D round of venture capital from a variety of investors.

Previous investors that participated in the new round include Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital. Also investing this time are Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.